Flotufolastat F 18
Prostate Adenocarcinoma
Icahn School of Medicine at Mount SinaiSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 73/ 100
Competitive context
88 Active assets in the Prostate Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel Instituto do Cancer do Estado de São Paulo | Phase 3 | BBB |
Nilutamide SWOG Cancer Research Network | Phase 3 | BB |
Prednisone Mayo Clinic | Phase 3 | BB |
Cyclophosphamide Beijing Biotech | Phase 2 | BB |
Degarelix Canadian Cancer Trials Group | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Flotufolastat F 18 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →